The Role of Platelets in the Pathogenesis of Thrombosis and Hemorrhage in Patients with Thrombocytosis

Summary

Some patients with thrombocytosis due to myeloproliferative diseases or other etiologies experience thromboembolic complications and others may bleed excessively. It seems unlikely that elevations in platelet count per se are a direct cause either of thrombosis or of hemorrhage. In an effort to ascertain whether variations in platelet function might determine whether an individual patient experiences thrombotic or hemorrhagic complications we have evaluated platelet function in 22patients with thrombocytosis due to a variety of etiologies. The results of platelet counts, bleeding time determinations, and studies of platelet aggregation were similar in patients with thrombosis, in patients with bleeding and in patients with neither complication. Therefore, detailed studies of platelet coagulant activities were carried out in 8patients. The results of platelet coagulant activity assays were normal in all 3patients with thrombocytosis and neither thrombotic nor bleeding complications and an additional 3patients with myeloproliferative diseases, normal platelet counts and no thrombohemorrhagic complications. In 2patients with thrombotic complications significant elevation of platelet coagulant activities concerned with the early phases of intrinsic coagulation were observed whereas in 2patients with severe hemorrhagic complications deficiences of either contact forming activity or collagen-induced coagulant activities were evident. This preliminary study suggests the possibility that variations in platelet coagulant activities concerned with the early stages of intrinsic coagulation may determine whether patients with thrombocytosis will experience bleeding or thrombotic complications.

• References

• 1 Adams T, Schutz L, Goldberg L. 1974; Platelet function abnormalities in the myeloproliferative disorders. Scandinavian Journal of Haematology 13: 215.
• 2 Barbui T, Battista R, Dini E. 1973; Spontaneous platelet aggregation in myeloproliferative disorders. Acta Haematologica 50: 25.
• 3 Bensinger T. A, Logue G. L, Rundles R. W. 1970; Hemorrhagic thrombocythemia; control of postsplenectomy thrombocytosis with melphalan. Blood 36: 61.
• 4 Berger S, Aledort L. M, Gilbert H. S, Hanson J. P, Wasserman L. R. 1973; Abnormalities of platelet function in patients with polycythemia vera. Cancer Research 33: 2683.
• 5 Bigelow F. S. 1954; Serotonin activity in blood: Measurements in normal subjects and in patients with thrombocythemia hemorrhagica and other hemorrhagic states. Journal of Laboratory and Clinical Medicine 43: 759.
• 6 Boughton B. J, Corbett W. E. N, Ginsburg A. D. 1977; Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function. Journal of Clinical Pathology 30: 228.
• 7 Brecher G, Cronkite E. P. 1950; Morphology and enumeration of human blood platelets. Journal of Applied Physiology 3: 365.
• 8 Brodsky I, Ross E. M, Petkov G, Kahn S. B. 1972; b Platelet and fibrinogen kinetics with [⁷⁵Se]-Selenomethionine in patients with myeloproliferative disorders. British Journal of Haematology 22: 179.
• 9 Brodsky I, Kahn S. B, Ross E. M, Petkov G. 1972; a Platelet and fibrinogen kinetics in the chronic myeloproliferative disorders. Cancer 30: 1444.
• 10 Cardamone J. M, Edson J. R, McArthur J. R, Jacob H. S. 1972; Abnormalities of platelet function in myeloproliferative disorders. Journal of the American Medical Association 221: 270.
• 11 Cohen I, Djaldetti M, Karp M, De Vries A. 1966; Thrombocytosis with impaired platelet adhesiveness and platelet factor 3 availability. New Istanbul Contributions to the Clinical Sciences 9: 20.
• 12 Dawson A. A, Ogston D. 1970; The influence of the platelet count on the incidence of thrombotic and haemorrhagic complications in polycythemia vera. Postgraduate Medical Journal 46: 76.
• 13 Didisheim P, Bunting D. 1966; Abnormal platelet function in myelofibrosis. The American Journal of Clinical Pathology 45: 566.
• 14 Drummond A. H, Gordon J. L. 1974; A rapid, sensitive microassay for platelet 5-HT. Thrombosis et Diathesis Haemorrhagica 31: 366.
• 15 Epstein E, Goedel A. 1934; Hämorrhagische Thrombocythämie bei vasculärer Schrumpfmilz. Virchows Archiv 292: 233.
• 16 Gilbert H. S. 1975; Definition, clinical features and diagnosis of polycythaemia vera. Clinics in Haematology 4: 263.
• 17 Ginsburg A. D. 1974. Thrombocytosis and thrombocythemia. In: Physiological Pharmacology. Vol. V. Blood. (eds.) Root W. S, Berlin N. I. Academic Press; New York: 199-235.
• 18 Ginsburg A. D. 1975; Platelet function in patients with high platelet counts. Annals of Internal Medicine 82: 506.
• 19 Gunz F. W. 1960; Hemorrhagic thrombocythemia: A critical review. Blood 15: 706.
• 20 Gunz F. W. 1972. Essential thrombocythemia, Chapter 83. In: Hematology. (eds.) Williams W. J, Beutler E, Erslev A. J, Rundles R. W. McGraw-Hill Book Co.; New York: 704.
• 21 Hardistry R. M, Wolff H. H. 1955; Haemorrhagic thrombocythaemia: a clinical and laboratory study. British Journal of Haematology 1: 390.
• 22 Harker L. A, Finch C. A. 1969; Thrombokinetics in man. Journal of Clinical Investigation 48: 963.
• 23 Hirsh J, Dacie J. V. 1966; Persistent postsplenectomy thrombocytosis and thromboembolism: a consequence of continuing anaemia. British Journal of Haematology 12: 44.
• 24 Holmsen H, Østvold A.-C, Day H. J. 1973; Behavior of endogenous and newly absorbed serotonin in the platelet release reaction. Biochemical Pharmacology 22: 2599.
• 25 Inceman S, Tangun Y. 1972; Platelet defects in the myeloproliferative disorders. Annals of the New York Academy of Science 201: 251.
• 26 Kutti J, Weinfeld A. 1971; Platelet survival in active polycythaemia vera with reference to the haematocrit level. Scandinavian Journal of Haematology 8: 405.
• 27 Laszlo J. 1975; Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD and hemorrhagic thrombocythemia. Seminars in Hematology 12: 409.
• 28 Martinez J, Shapiro S. S, Holburn R. R. 1973; Metabolism of human prothrombin and fibrinogen in patients with thrombocytosis secondary to myeloproliferative states. Blood 42: 35.
• 29 Mason Jr J. E, De Vita V. T, Canellos G. P. 1974; Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood 44: 438.
• 30 McClure P. D, Ingram G. I. C, Stacey R. S, Glass U. H, Matchett M. O. 1966; Platelet function test in thrombocythaemia and thrombocytosis. British Journal of Haematology 12: 478.
• 31 Milstone J. H. 1964; Thrombokinase as prime activator of prothrombin: historical perspectives and present status. Federation Proceedings 23: 742.
• 32 Monto R. W, Griest W. D, Szilagyi D. E. 1952; Essential thrombophilia. Archives of Internal Medicine 90: 54.
• 33 Neemeh J. A, Bowie E. J. W, Thompson Fr J. H, Didisheim P, Owen Jr C. A. 1972; Quantitation of platelet aggregation in myeloproliferative disorders. American Journal of Clinical Pathology 57: 336.
• 34 Nygaard K. K, Brown G. E. 1937; Essential thrombophilia. Archives of Internal Medicine 59: 83.
• 35 Ozer F. L, Truax W. E, Miesch D. C, Levin W. C. 1960; Primary hemorrhagic thrombocythemia. American Journal of Medicine 28: 807.
• 36 Preston F. E, Emmanuel I. G, Winfield D. A, Malia R. G. 1974; Essential thrombocythaemia and peripheral gangrene. British Medical Journal 3: 548.
• 37 Rigby P. G, Leavell B. S. 1960; Polycythemia vera. Archives of Internal Medicine 5: 100.
• 38 Spaet T. H, Lejnieks I, Gaynor E, Goldstein M. L. 1969; Defective platelets in essential thrombocythemia. Archives of Internal Medicine 124: 135.
• 39 Takácsi-Nagy L, Gráf F. 1975; Definition, clinical features and diagnosis of myelofibrosis. Clinics in Haematology 4: 291.
• 40 Taylor D. D, Senhauser D. A, Cavazos F. 1968; Thrombocytopathy associated with nonleukemic megakaryocytic myelosis. Functional and fine structure observations of the abnormal platelets. The American Journal of Clinical Pathology 49: 662.
• 41 Vreeken J, Van Aken W. G. 1971; Spontaneous aggregation of blood platelets as a cause of idiopathic thrombosis and recurrent painful toes and fingers. Lancet II: 1394.
• 42 Walsh P. N. 1972; a Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities. British Journal of Haematology 22: 205.
• 43 Walsh P. N. 1972; b The effect of dilution of plasma on coagulation. The significance of the dilution – activation phenomenon for the study of platelet coagulant activities. British Journal of Haematology 22: 219.
• 44 Walsh P. N. 1972; c The role of platelets in the contact phase of blood coagulation. British Journal of Haematology 22: 237.
• 45 Walsh P. N. 1972; d The effects of collagen and kaolin on the intrinsic coagulant activity of platelets. Evidence for an alternative pathway in intrinsic coagulation not requiring factor XII. British Journal of Haematology 22: 393.
• 46 Walsh P. N. 1972; e Platelet coagulant activities in thrombasthenia. British Journal of Haematology 23: 553.
• 47 Walsh P. N, Biggs R. 1972; The role of platelets in intrinsic factor-Xa formation. British Journal of Haematology 22: 743.
• 48 Walsh P. N, Mills D. C. B, Pareti F. I, Stewart G. J, Macfarlane D. E, Johnson M. E, Egan J. J. 1975; Hereditary giant platelet syndrome. Absence of collagen-induced coagulant activity and deficiency of factor-XI binding to platelets. British Journal of Haematology 29: 639.
• 49 Walsh P. N, Pareti F. I, Corbett J. J. 1976; Platelet coagulant activities and serum lipids in transient cerebral ischemia. New England Journal of Medicine 295: 854.
• 50 Walsh P. N, Mills D. C. B, White J. G. 1977; Metabolism and function of human platelets washed by albumin density gradient separation. British Journal of Haematology 36: 285.
• 51 Wasserman L. R, Gilbert H. S. 1963; Surgery in polycythemia vera. The New England Journal of Medicine 269: 1226.
• 52 Wasserman L. R, Gilbert H. S. 1966; Complications of polycythemia vera. Seminars in Hematology 3: 199.
• 53 Weinfeld A, Branehög I, Kutti J. 1975; Platelets in the myeloproliferative syndrome. Clinics in Haematology 4: 373.
• 54 Zahavi J, Marder V. J. 1974; Acquired “Storage pool disease” of platelets associated with circulating antiplatelet antibodies. The American Journal of Medicine 56: 883.
• 55 Zucker S, Mielke C. H. 1972; Classification of thrombocytosis based on platelet function tests: correlation with hemorrhagic and thrombotic complications. The Journal of Laboratory and Clinical Medicine 80: 385.